Marimastat

This page contains recent news articles, when available, and an overview of Marimastat but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Marimastat (when available)

Pharmacology and use:
Used in the treatment of cancer, it is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes. For the treatment of various cancers

Mechanism Of Action:
Marimastat is a hydroxamic acid, matrix metalloprotease inhibitor. It mimics the peptide structure of natural MMP substrates. It binds to matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tymor cells into existing blood cells, thereby preventing metastasis.

News Articles on Marimastat

Vernalis snaps up rival biotechnology company  -  Jul 7, 2005
The company was formed from British Biotech - which rose to fame after investigations into claims it had made about so-called "miracle drug" marimastat that ... Telegraph.co.uk

Study provides clues to prevent spread of ovarian cancer  -  Mar 15, 2008
Several drugs known as MMP inhibitors (for example, marimastat or ... In the earlier trial, marimastat was given to women with late-stage disease that had ... Hindu

AZ sales leap but another drug fails. | Article from The Evening...  -  Oct 26, 2006
TROUBLED British Biotech saw its shares tumble 11% today to 24p, down 3p, as further tests on what was hoped to be a miracle cancer cure, Marimastat, ... Pay-Per-View - Evening Standard - HighBeam Research

… with glioblastoma do not respond to the anti-enzyme therapy marimas...  -  Aug 29, 2006
Levin and colleagues published their study in the Journal of Neuro-Oncology (Randomized, double-blind, placebo-controlled trial of marimastat in ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Brain Tumor - Adults Other Treatments - Brain Tumor - Adults Health …  -  Jun 10, 2008
Inhibitors of these enzymes, including marimastat, metastat, and prinomastat ... Marimastat has been studied and has shown some benefits in early trials for ... New York Times

Drug chief returns...seven years after swallowing a bitter pill  -  Jan 9, 2006
British Biotech shot to prominence on the back of claims about cancer drug Marimastat. But the company was hit by scandal when head of clinical research ... Telegraph.co.uk

Clues To Prevent Spread Of Ovarian Cancer  -  Mar 18, 2008
Several drugs known as MMP inhibitors (for example, marimastat or ... In the earlier trial, marimastat was given to women with late-stage disease that had ... sciencedaily.com

Ten years of biotech gaffes  -  Mar 8, 2006
All of the investors' chips were being placed on British Biotech's lead compound, marimastat, an orally available matrix metalloproteinase inhibitor (MMPI) ... Nature.com

Rugby Union: Heineken Cup boycott slammed as 'disgraceful' by IRB …  -  Apr 10, 2007
In a comprehensive 30-page circular to ... was intending to find a US marketing partner for Marimastat. Dr Millar said he was still concerned about the way ... Pay-Per-View - Birmingham Post - HighBeam Research

SEC Charges Biotech Co. for Unregistered Stock Sales  -  Jul 11, 2006
The Oxford-based company made false statements regarding “Marimastat,�? its main ... According to some studies, Marimastat provides survival rates equal to ... CCH Wall Street

The long process from a jungle plant to a pill bottle  -  Feb 9, 2007
This is the point at which the promising anti-cancer drug Marimastat, from British Biotech, was cast into doubt. It was hoped to offer similar survival ... Times Online

Ex-British Biotech chief in comeback. | Article from Sunday Business...  -  Mar 19, 2006
IT is two years since British Biotech hit the headlines in a blaze ... for Marimastat. The "new" British Biotech will focus on antibiotics ... that this ... Pay-Per-View - Sunday Business - HighBeam Research

Asthma hope in cancer drug  -  Nov 22, 2005
Dr Thomas, from the university's medical faculty, found the drug, marimastat, made asthma sufferers less sensitive to allergens which could set off an ... Sydney Morning Herald

Harvard University; ADAM 12 cleaves extracellular matrix proteins, …  -  Feb 16, 2005
...of ADAM 12 was completely abrogated by zinc chelators 1,10-phenanthroline and EDTA and was partially inhibited by the hydroxamate inhibitor Marimastat. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones

Article: An upbeat earnings outlook and favourable news... [Derived …  -  Sep 7, 2007
He believes the market has misinterpreted the recent data on its Marimastat cancer drug and expects favourable news soon on Lexipafant, a pancreatitis ... Pay-Per-View - Independent - London - HighBeam Research

Article: ML Laboratories parts company with executive chairman.( …  -  Mar 4, 2005
MAGNUS GRIMOND Two directors in ML Laboratories, the fledgling pharmaceutical company, have made a pounds ... promising results for its Marimastat ... Pay-Per-View - Daily Post - HighBeam Research

C& W sets deadline for Thus bid talks ; IN BRIEF | Article from...  -  Jun 6, 2008
THE Canadian boss of troubled British Biotech, Elliot Goldstein, has set a deadline of just a few months for tests on its anticancer drug Marimastat to ... Pay-Per-View - Evening Standard - London - HighBeam Research

Shire in biotech deal with US firm | Article from The Independent -...  -  Nov 9, 2007
British Biotech has taken a big step in completing world-wide distribution for its Marimastat anti-cancer drug with the announcement of a $74m (pounds ... Pay-Per-View - Independent - London - HighBeam Research

Article: ML Laboratories' investors want new faces. - Investors...  -  Feb 25, 2005
MAGNUS GRIMOND Two directors in ML Laboratories, the fledgling pharmaceutical company, have made a pounds ... promising results for its Marimastat ... Pay-Per-View - Investors Chronicle - HighBeam Research

The Ten Best Rose gardens ; EXTRA | Article from The Independent - …  -  May 28, 2007
The Independent - London; November 9, 1996 ; 700+ words ... ... its Marimastat cancer drug and expects favourable news soon on Lexipafant, a pancreatitis ... Pay-Per-View - Independent - London - HighBeam Research

Ex-British Biotech Chief in Comeback  -  Mar 21, 2006
...claimed McCullagh and others had over-puffed test results for the company's drugs, including marimastat, once hailed as a miracle cancer cure. ... RedOrbit

Free rape drug test kits.(News) | Article from The News Letter...  -  Aug 5, 2005
FORMER stock market darling British Biotech saw its shares dive 22 per cent yesterday after reporting disappointing test results from its marimastat cancer ... Pay-Per-View - News Letter - HighBeam Research

Ex-British Biotech chief in comeback.  -  Mar 19, 2006
...claimed McCullagh and others had over-puffed test results for the company's drugs, including marimastat, once hailed as a miracle cancer cure. ... Free with registration - Sunday Business - AccessMyLibrary.com

A few home truths ; An apple a day keeps the doctor away; feed a...  -  Apr 10, 2007
Recent test results from Marimastat showed that up to a third of patients suffered pains in the arms and shoulders after ... ... Pay-Per-View - Independent - London - HighBeam Research

Breast Cancer; ADAM 12 cleaves extracellular matrix proteins,...  -  Feb 19, 2005
...of ADAM 12 was completely abrogated by zinc chelators 1,10-phenanthroline and EDTA and was partially inhibited by the hydroxamate inhibitor Marimastat. ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones

Matrix metalloproteinase-2 is a consistent prognostic factor in...  -  Feb 2, 2006
Maughan T, Brown PD, Baillet M, Fielding JW (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. ... Nature.com

Breast Cancer; ADAM 12 cleaves extracellular matrix proteins,...  -  Feb 14, 2005
...of ADAM 12 was completely abrogated by zinc chelators 1,10-phenanthroline and EDTA and was partially inhibited by the hydroxamate inhibitor Marimastat. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones

Profit-taking leads City into the red.(Business) | Article from The...  -  Nov 17, 2005
July 6, 2000 ; 653 words ... ... been hit last month when the group announced disappointing results of its anti-cancer drug Marimastat. ... Pay-Per-View - News Letter - HighBeam Research

Article: NSW: McGrath in training as wife nears cancer recovery - AAP...  -  Jun 20, 2006
...is to announce a partnership deal with a major pharmaceutical company by the end of this week to develop its Marimastat cancer treatment. ... Pay-Per-View - AAP General News - HighBeam Research

Article: Crik: McGrath in training as wife nears cancer recovery -...  -  Jun 21, 2006
...is to announce a partnership deal with a major pharmaceutical company by the end of this week to develop its Marimastat cancer treatment. ... Pay-Per-View - AAP Sports News - HighBeam Research

… INDUSTRY : COMMISSION CLEARS ACQUISITION OF SCHERING BY …  -  May 31, 2006
British Biotech plc agreed to a deal with Schering-PloughCorp. for the development and marketing of its oral ... completing the current Marimastat trial ... Pay-Per-View - European Report - HighBeam Research

Abortion pill chemical 'could fight breast and ovarian cancers' ;...  -  Dec 1, 2006
Abortion pill chemical 'could fight breast and ovarian cancers' ; Home News IN BRIEF ... find The Independent - London articles. The chemical mifepristone ... Pay-Per-View - Independent - London - HighBeam Research

NATIONAL & INTERNATIONAL: Drug trials will continue.(News) | Article ...  -  Mar 25, 2006
...treatment showed no significant benefits. Clinical trials of marimastat on pancreatic cancer patients had "failed to show significant improvement in ... Pay-Per-View - Birmingham Post - HighBeam Research

SkyePharma rises on drug approval ; Business News IN BRIEF | Article ...  -  Dec 19, 2006
...the drugs group which has had an eventful time as the stock market has sought to judge the potential value of its cancer drug, Marimastat. ... Pay-Per-View - Independent - London - HighBeam Research

Drug trials 'should use sick patients'.(News) | Article from The...  -  Jul 26, 2006
...treatment showed no significant benefits. Clinical trials of marimastat on pancreatic cancer patients had "failed to show significant improvement in ... Pay-Per-View - Birmingham Post - HighBeam Research

Brand Names/Synonyms:
Marimastat is also known by the following brand names and/or synonymsBB 2516; BB 2516;; BB-2516; Marimastat; Marimastat [Usan]

Drug Category:
Marimastat is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01X

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
N-[2,2-dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4-methyl-pentanamide

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.